The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.

O'Sullivan JM., Hamblin A., Yap C., Fox S., Boucher R., Panchal A., Alimam S., Dreau H., Howard K., Ware P., Cross NCP., McMullin MF., Harrison CN., Mead AJ.

DOI

10.1182/blood.2019001861

Type

Journal article

Journal

Blood

Publication Date

05/12/2019

Volume

134

Pages

2107 - 2111

Permalink Original publication